A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

A liquid material including a polysaccharide is manufactured by creating a mixture of polysaccharides and an aqueous solvent or an aqueous cosolvent with organic solvents at a temperature at which gelation does not occur. The mixture is also irradiated at this lower temperature, such as with ultrasound waves in combination with stirring and/or bubbling of inert gases. to apply ultrasound to a mixture of. Compared with conventional reactions with low concentration solutions, the product yield and advantageous mechanical properties are significantly increased. Depolymerization (decomposition, disassembly) of polysaccharide in the liquid material does not occur to any substantial degree, and the molecular structure of the polysaccharide is maintained. Further, the liquid material does not gel even when the temperature is raised, and thus, its fluidity is maintained, despite polysaccharides being maintained at a high concentration. The liquid material is applicable to myriad industries, including pharmaceuticals and health foods.

The object of the present invention is a new cryopolymerization process that provides crosslinked polymeric materials in the form of a macroporous gel (cryogel) capable of sequestering (neutralize) the anticoagulant heparin, its low molecular weight derivatives (LMWH and ULMWH) and heparinoids, from aqueous solutions, physiological solutions and biological fluids, such as whole blood, serum and plasma. A further object of the invention are also crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtained by the cryopolymerization process of the invention that, thanks to said specific process, result to be comprised of varying proportions of HEMA and HEMA-R monomers. The molar ratio between the components (HEMA/HEMA-R) may vary between 99.9% HEMA:0.1% HEMA-R and 0.1% HEMA:99.9% HEMA-R. Object of the invention is also the use of crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtainable by the cryopolymerization process of the invention for the construction of filters, membranes or devices for the treatment of biological fluids. A further object of the invention are therefore filters, membranes, or devices for the treatment of biological fluids which comprise materials obtained by the cryopolymerization process of the invention.

The object of the present invention is a new cryopolymerization process that provides crosslinked polymeric materials in the form of a macroporous gel (cryogel) capable of sequestering (neutralize) the anticoagulant heparin, its low molecular weight derivatives (LMWH and ULMWH) and heparinoids, from aqueous solutions, physiological solutions and biological fluids, such as whole blood, serum and plasma. A further object of the invention are also crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtained by the cryopolymerization process of the invention that, thanks to said specific process, result to be comprised of varying proportions of HEMA and HEMA-R monomers. The molar ratio between the components (HEMA/HEMA-R) may vary between 99.9% HEMA:0.1% HEMA-R and 0.1% HEMA:99.9% HEMA-R. Object of the invention is also the use of crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtainable by the cryopolymerization process of the invention for the construction of filters, membranes or devices for the treatment of biological fluids. A further object of the invention are therefore filters, membranes, or devices for the treatment of biological fluids which comprise materials obtained by the cryopolymerization process of the invention.

A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.

There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.

The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.